Drug firm Sanofi-Synthelabo India has expanded Sanofi's diabetes portfolio in the country with launch of two drugs - Lyxumia and Zemiglo - for lowering blood sugar levels.
While Lyxumia is a once daily, non-insulin injectable drug, Zemiglo is a once daily, oral tablet, Sanofi-Synthelabo (India) Pvt Ltd said in a statement.
Commenting on the development, Sanofi India Pharmaceutical Operations Country Head & General Manager N Rajaram said: "The launch of two additions to Sanofi India portfolio - Lyxumia and Zemiglo, is our step forward in developing new solutions for people with type 2 diabetes."
It is also a testament to Sanofi India's commitment to help address the current treatment gaps in the country, he added.
Lyxumia is currently approved in over 70 countries worldwide for the treatment of type 2 diabetes, with commercial launches in most EU countries, Japan, Brazil, Mexico and other markets. It has been filed in the US for approvals, the company said.
Zemiglo has been approved in South Korea in 2012 and already has over three years of clinical experience.
